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Abstract
Background Primary hyperparathyroidism is the most common manifestation of multiple endocrine neoplasia type 1
(MEN1). Guidelines advocate subtotal parathyroidectomy (STP) or total parathyroidectomy with autotransplantation
due to high prevalence of multiglandular disease; however, both are associated with a significant risk of permanent
hypoparathyroidism. More accurate imaging and use of intraoperative PTH levels may allow a less extensive initial
parathyroidectomy (unilateral clearance, removing both parathyroids with cervical thymectomy) in selected MEN1
patients with primary hyperparathyroidism.
Methods We performed a retrospective cohort study at a high-volume tertiary medical center including patients with
MEN1 and primary hyperparathyroidism, who underwent STP or unilateral clearance as their initial surgery from
1995 to 2015. Unilateral clearance was offered to patients who had concordant sestamibi and ultrasound showing a
single enlarged parathyroid gland. For both the groups, we compared rates of persistent/recurrent disease and
permanent hypoparathyroidism.
Results Eight patients had unilateral clearance and 16 had STP. Subtotal parathyroidectomy patients were younger
(37 vs 52 years). One patient in each group had persistent disease. One (13 %) unilateral clearance and five (31 %)
STP patients had recurrent hyperparathyroidism after a mean follow-up of 47 and 68 months (p = 0.62). No uni-
lateral clearance patients and two of 16 SPT patients had permanent hypoparathyroidism (p = 0.54).
Conclusions Some MEN1 patients with primary hyperparathyroidism who have concordant localizing studies may
be selected for unilateral clearance as an alternative to STP. For appropriately selected MEN1 patients, unilateral
clearance can achieve similar results as STP and has no risk of permanent hypoparathyroidism, and may facilitate
possible future reoperations.
Introduction
Primary hyperparathyroidism is often the first manifesta-
tion of multiple endocrine neoplasia type 1 (MEN1) with
100 % penetrance by age 65 [1]. Patients with MEN 1
usually have multiple abnormally appearing parathyroid
glands (‘‘asymmetrical hyperplasia’’). In contrast, 80 % of
patients with sporadic primary hyperparathyroidism have a
single adenoma [2]. Since all the glands in patients with
MEN1 have the menin mutation, any parathyroid tissue left
in the patient is at risk for growing and developing into a
hyperfunctioning gland. To achieve the lowest possible rate
The results of this study were presented on stage at the 2016 Pacific
Coast Surgical Association meeting, Big Island, Hawaii.
& Wouter P. Kluijfhout
wpkluijfhout@gmail.com
1 Department of Surgery, University of California, Mt Zion,
1600 Divisadero Street, San Francisco, CA 94115, USA
2 Department of Surgery, University Medical Center Utrecht,
Utrecht, The Netherlands
3 Division of Endocrinology, University of California,
San Francisco, CA, USA
123
World J Surg (2016) 40:2964–2969
DOI 10.1007/s00268-016-3624-9
of recurrent disease, surgeons traditionally have advocated
most aggressive resection leaving as little parathyroid tis-
sue as possible [3, 4]. Therefore, current guidelines rec-
ommend performing either subtotal (3 1/2)
parathyroidectomy or total parathyroidectomy with fore-
arm autotransplantation at initial operation [5]. Aggressive
resection of parathyroid glands, however, also leads to a
higher risk of permanent hypoparathyroidism, which can
greatly affect patients’ quality of life [3, 6–10].
Several reports have shown that some patients do not
develop recurrent disease even after long follow-up,
despite less aggressive initial operation [8, 11]. With the
increasing ability to preoperatively localize large and
hyperfunctioning parathyroid tumors and intraoperatively
monitor PTH levels, some surgeons have begun to perform
less aggressive initial parathyroidectomy in order to lower
the risk of permanent hypoparathyroidism [8, 9]. To avoid
re-exploration in a scarred neck, a new strategy has been
proposed. During a ‘‘unilateral clearance,’’ both the
abnormal gland and other parathyroid tissues from the
same side of the neck (the other parathyroid and the cer-
vical thymus) are removed in patients with MEN1 and
primary hyperparathyroidism. We retrospectively reviewed
the results of unilateral clearance in eligible MEN1 patients
in our institution over the past 15 years. We examined the
rates of permanent hypoparathyroidism and persistent or
recurrent disease in this cohort and compared them to the
results of traditional STP.
Material and methods
Surgical strategy for primary hyperparathyroidism
in MEN1 patients
Our previous standard surgical approach to MEN1 patients
with primary hyperparathyroidism was STP. Preoperative
localization studies were not routinely performed. A tra-
ditional bilateral neck exploration was performed, with
inspection of all four parathyroid glands and identification
of potential supernumerary glands. The most normal-ap-
pearing gland was then biopsied, marked with a clip, and a
50-mg remnant was left in situ to prevent postoperative
hypoparathyroidism. The other three glands as well as the
cervical thymus were removed [11].
Since 2000, with increasing and routine use of preop-
erative sestamibi scans and ultrasound, we began to iden-
tify a subgroup of MEN1 patients with a preoperatively
located single abnormal parathyroid gland. For this sub-
group of patients, we start the operation by finding and
excising the abnormal gland, followed by excising the
other gland on the same side as well as the ipsilateral
cervical thymus. We use intraoperative PTH (IOPTH)
monitoring to look for a significant drop. If the 10-min
postexcision PTH adequately drops by more than 50 %
from baseline, the other side is not explored.
Patients
All patients with MEN1 and primary hyperparathyroidism,
who had their initial operation at UCSF between 1995 and
2015 were included in the study. The diagnosis of MEN1
was based on (1) proven genetic mutation, (2) coexisting
endocrine neoplastic disease in the pancreas, duodenum or
pituitary gland, or (3) at least one first-degree relative with
MEN1 [5]. This study was reviewed and approved by the
local institutional review boards.
Outcomes
Persistent hyperparathyroidism was defined as elevated
serum calcium levels with inappropriately elevated levels
of PTH within 6 months of initial parathyroidectomy, and
recurrent hyperparathyroidism as increased levels of cal-
cium and PTH after at least 6 months of follow-up with
normalization of serum levels of calcium and PTH after
initial parathyroidectomy. Permanent hypoparathyroidism
was defined by serum calcium levels below the normal
range and requirement for supplemental calcium and
vitamin D after 6 months following operation.
Serum calcium was measured using a UniCel DxC 800
Clinical system (Beckman Coulter), with reference level
8.8–10.3 mg/dL. Intraoperative PTH was measured using a
UniCel DxI 600 Immunoassay system (Beckman Coulter).
Intact PTH was measured with Immulite 2000
Immunoassay (Siemens Healthcare), with reference level
of 12–65 ng/L.
Statistical analysis
Standard descriptive statistics (mean, range and frequency)
were used to analyze patients and disease characteristics.
Fisher’s exact test was used to compare incidence of
recurrent disease, persistent disease, and permanent
hypoparathyroidism. Student T-test was used to compare
continuous variables between the two surgical groups. A
p value of less than 0.05 was considered statistically sig-
nificant. All data analyses were performed using SPSS
version 21.0 (SPSS Inc., Chicago, IL).
Results
Eight patients underwent unilateral clearance during the
study period. There were five (63 %) women and three
men; the mean age was 52 (Table 1). After a mean follow-
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up of 47 (range 2–112) months, one patient (Patient 2)
developed recurrent disease 8 years after initial operation,
with a CT scan showing a lesion suspicious for parathyroid
adenoma in the left tracheoesophageal groove on the same
side as the initial unilateral clearance, and is being treated
with cinacalcet due to the interval development of widely
metastatic neuroendocrine tumor. Patient 8 had persistent
disease. She underwent a right-sided unilateral clearance of
the abnormal lower gland shown by concordant sestamibi
and ultrasound and the upper ipsilateral gland and cervical
thymus, with a drop in IOPTH from 389 ng/L preincision
to 109 ng/L postexcision (via internal jugular). 2 weeks
postoperatively, she had elevated serum levels of PTH (94
vs 138 ng/L preoperatively) and calcium (10.5 vs 11 mg/
dL preoperatively). Repeat imaging with US and sestamibi
showed an additional abnormal left lower parathyroid. She
then underwent exploration of the left side, with excision
of a 1.5-cm tumor and biopsy of the other gland. After this
second operation, she had transient hypocalcemia, but has
remained normocalcemic since then (50 months of follow-
up). No patient had permanent hypoparathyroidism.
The 16 MEN1 patients who underwent STP during the
same period were significantly younger than those who
underwent unilateral clearance (37 vs 52 years, p = 0.027)
(Table 2). None of these patients were scheduled for initial
unilateral clearance, since they either did not have con-
cordant imaging for one abnormal gland, or due to surgeon
preference. After a mean follow-up of 68 (range 1–223)
months, five of 16 patients had recurrent disease at 2, 5, 8,
8, and 15 years, respectively. One patient underwent a right
neck re-exploration with removal of the residual right
lower gland with normocalcemia at follow-up. One patient
underwent an unknown second operation at an outside
center, which did not cure her hyperparathyroidism, and is
currently being treated with cinacalcet. One patient had a
successful reoperation (left neck re-exploration with
removal of regrown left lower parathyroid) but again
recurred 3 years after the second operation and is now
Table 1 Multiple endocrine neoplasia type 1 patients (n = 8) who underwent unilateral clearance for primary hyperparathyroidism









1 F 46 Pituitary 13.2 583 No No No 2
2 M 33 Gastrinoma 10.2 106 No Yesa No 106
3 F 35 Insulinoma 11.1 127 No No No 112
4 M 65 Pituitary 9.8 204 No No No 33
5 F 68 Pituitary Pancreatic 10.9 90 No No No 10
6 M 65 Pituitary 11.5 92 No No No 6
7 F 51 Pancreatic 11.4 115 No No No 59
8 M 59 -b 11.2 138 Yes No Temporaryc 50
F female, M male, PTH parathormone
a Eight years after initial parathyroidectomy
b Diagnosis based on genetic mutation
c After reoperation
Table 2 Comparison between patients who underwent subtotal parathyroidectomy and those who underwent unilateral clearance for primary
hyperparathyroidism
Subtotal parathyroidectomy N = 16 Unilateral approach N = 8 P value
Age, mean (range) 37 52 0.027






Permanent hypoparathyroidism 2 (13 %) 0 (0 %) 0.536
Persistent disease 1 (6 %) 1 (13 %) 1.000
Recurrent disease 5 (31 %) 1 (13 %) 0.621
Follow-up (months) 68 47 0.454
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being medically managed. One patient had a completion
parathyroidectomy with failed autotransplant to the fore-
arm and developed permanent hypoparathyroidism. The
last patient did not undergo a second surgery due to
comorbidities and is also being medically managed. One
patient who had persistent disease after an STP was fol-
lowed for 3 years and then underwent a successful resec-
tion of the remnant right upper parathyroid with
autotransplant. Overall, two of the 16 patients developed
permanent hypoparathyroidism, one after initial STP and
one after reoperation.
Discussion
In this study, we found that unilateral clearance can be
performed in a subgroup of MEN1 patients with primary
hyperparathyroidism who have concordant preoperative
sestamibi and ultrasound localization studies. In these
selected patients, using this less aggressive approach, the
risk of permanent hypocalcemia is lower without a sig-
nificantly increased risk of recurrent or persistent disease.
There are three goals for parathyroidectomy in MEN1
patients: correct hypercalcemia, avoid permanent
hypoparathyroidism, and facilitate potential future opera-
tion [12]. The current MEN1 guidelines focus primarily on
correcting hypercalcemia, both immediately (avoid per-
sistent disease) and in the long term (avoid recurrent dis-
ease). Most experienced parathyroid surgeons recommend
either STP or total parathyroidectomy with autotransplan-
tation [3, 5–13]. Both have low recurrence rates, but still
have some risk of permanent hypoparathyroidism.
Conceptually, the current recommendations apply the
same operation to all patients with MEN1 using a relatively
aggressive operation in order to lower the risk of recur-
rence. It is very likely, however, that not all MEN1 patients
have the same aggressive parathyroid disease. There are
more than 1000 germline mutations reported [14–16]. If we
hypothesize MEN1 parathyroid disease to have a spectrum
of aggressiveness (defined in terms of number of parathy-
roid glands involved), then conceptually it is not wrong to
treat those with less aggressive disease with a less
aggressive parathyroid operation. Once we make this
conceptual leap, then the question becomes how do we
identify those MEN1 patients who may have a less
aggressive manifestation of hyperparathyroidism and treat
them less aggressively.
It is possible that genetic heterogeneity will eventually
help us to predict the aggressiveness of parathyroid disease
[14]. The first proposal for a subdivision based on genotype
was published in 2000 by Bartsch et al [17]. In a study
investigating the outcome of patients with pancreatico-
duodenal tumors, they found that truncating nonsense or
frameshift mutations in the N- or C-terminal regions (exons
2, 9, 10) had a significantly higher rate of malignant
tumors. Using this same genotype-phenotype comparison
for primary hyperparathyroidism, another study has shown
that after surgical intervention with less than STP, patients
with these nonsense or frameshift mutations in exons 2, 9,
and 10 have a significantly lower risk of persistent or
recurrent disease than patients with other mutations [14].
Unfortunately, exact genetic mutations were only available
in 7/24 (29 %) of our cases, and therefore we could not
perform such a subanalysis. For now, however, localizing
studies may help us identify a subgroup of patients that can
be treated with less aggressive surgery.
Our patients who underwent unilateral clearance are a
highly selected group. These patients had two concordant
localizing studies for a single tumor. Localizing studies
such as sestamibi and ultrasound are only about 80–90 %
accurate for single gland diseased and much less accurate
for patients with multiple gland disease, and therefore
cannot be relied on completely for surgical decision-mak-
ing [18, 19]. However, even in MEN1 patients, these
localization studies may distinguish those with multiple
large tumors from those with a single tumor. In other
words, the localizing studies are used not just to find
tumors but also to categorize patients into those who are
more or less likely to have multiple large tumors. The
patients who have only a single radiographically identified
tumor are a different group and are more likely to have less
aggressive parathyroid disease. This concept is supported
by the observation that patients undergoing unilateral
clearance were significantly older at parathyroidectomy. It
is therefore not that surprising that the recurrence rate in
this group was not higher than those who underwent a more
aggressive operation of STP. Of the patients with at least
6 months follow-up, recurrent disease occurred in only one
(14 %) of the seven unilateral clearance patients versus five
(38 %) out of 13 patients who underwent STP. Although
the follow-up for the latter was substantially longer, 83
versus 53 months, respectively, this difference was not
significant.
In the unilateral clearance group, one patient had per-
sistent disease and underwent contralateral exploration
within 2 weeks of the initial surgery. The initial ultrasound,
however, should not have missed this second 1.5 cm large
tumor which was clearly visible at follow-up ultrasound
2 weeks later. This finding underscores the fact that
ultrasound is operator dependent. In addition, during the
initial surgery, the PTH dropped from 389 preincision to
109 postexcision. Even though this is a[50 % drop, PTH
was still substantially elevated and should have raised
suspicion for additional unresected disease. In all other
cases, IOPTH dropped into normal range (\65 ng/L). This
finding supports the observation that not all patients with a
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drop of at least 50 % in PTH are cured and the absolute
postoperative PTH level should be taken into account as
well [20]. One patient had recurrent disease 8 years after
unilateral clearance. The recurrence was on the same side
of the initial operation. He would likely have had a similar
recurrence, if he initially had an STP, since it was a
supernumerary gland.
The second goal of MEN 1-related parathyroidectomy is
the prevention of permanent hypoparathyroidism. The
same studies that showed a favorable outcome in terms of
persistent and recurrent disease for (sub) total parathy-
roidectomy versus less than STP revealed that between 7
and 67 % of patients suffer from permanent hypoparathy-
roidism, greatly affecting patients’ quality of life [3, 6–10].
In our study, none of the patients who underwent the uni-
lateral approach developed permanent hypoparathyroidism
versus two patients who underwent STP. Although the
difference was not significant due to our small sample size,
the result is supported by the literature showing less risk of
hypoparathyroidism for patients who undergo less than
STP [8, 9, 21, 22].
The last goal of surgery in these patients is the facili-
tation of future surgery. During the unilateral clearance,
both ipsilateral glands as well as the thymus are removed,
and the neck is carefully inspected for supernumerary
glands. By using this strategy, we reduced the likelihood of
re-exploring the same side of the neck in case of persistent
or recurrent disease. As suggested by the guidelines, doing
less than STP might indeed be associated with a higher
incidence of recurrent disease at long-term follow-up.
However, there is often an asynchronous presentation of
parathyroid tumors, which thus resecting only the large
hyperfunctioning glands may serve as an alternative oper-
ation with fewer complications [9]. As shown by our data,
patients undergoing unilateral clearance can be normocal-
cemic for years, with no risk of permanent hypoparathy-
roidism associated with (sub) total parathyroidectomy.
Traditionally, reoperation is considered a failure, but in
the case of MEN1-related primary hyperparathyroidism,
we recommend redefining goals and expectations.
Balancing potential risks and consequences of permanent
hypoparathyroidism, an initially less aggressive resection
appears to be appropriate in the subgroup of patients with
concordant imaging showing a single tumor. If a second
operation is necessary, it will most likely be in the previ-
ously nonoperative side of the neck.
There are several important limitations to this study. The
group that underwent unilateral clearance was highly
selected, and may be genetically different from the group
that underwent STP. The results found can therefore
potentially be explained by disease biology rather than the
surgery that was performed. Furthermore, our limited
sample size may not have been sufficient to detect
differences between the two groups. A recent publication
from the National Institute of Health regarding this topic
included 99 patients with MEN1. Although they concluded
that limited parathyroidectomy was a setup for failure, they
had only eight patients with concordant imaging studies
similar to our patients, and no subanalysis was performed on
this group [4]. A multicenter study will be helpful to address
this shortcoming. In addition, our limited follow-up period
may underestimate the true incidence of recurrent disease.
Nevertheless, we believe that our results clearly show
that there is a subgroup of MEN1 patients with concordant
imaging studies who could benefit from unilateral clear-
ance with resultant lower risk of permanent hypoparathy-
roidism. The potential need for subsequent reoperation
should not be considered a surgical failure, but a calculated
risk in order to maximize the opportunity to prevent
complications at the initial surgery.
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